Webinar “Predictive Disease Models for CNS Drug Development“

In November 2018, Birgit Hutter-Paier, PhD, the Director of Neuropharmacology at QPS Austria presented this webinar about validated transgenic and non-transgenic in vitro and in vivo models covering most targets of AD, PD, HD and other neurodegenerative diseases.

qpson_antibodypic1

You will learn:
  • When to use animal models in your drug discovery program
  • How to choose the most appropriate animal model for your therapeutic or mechanism of action
  • How to design the most efficient “first-pass” proof-of-concept study
  • Best practices for submitting compounds and sample requirements for a successful study

Brought to you by ADDF ACCESS, a program of the ADDF and Science Exchange, as part of their commitment to connect researchers developing CNS drugs with technologies that can help accelerate breakthrough discoveries.

Format: 30 minutes with 10 minutes Q&A

Watch recording!

top
20 years in pharma R&D navigation